The Life Sciences team advised Moderna, Inc. (Nasdaq: MRNA) on its underwritten public offering of 17,600,000 shares of common stock at a public offering price of $76.00 per share, before underwriting discounts and commissions. In addition, Moderna has granted the underwriters a 30-day option to purchase up to an additional 2,640,000 shares of common stock at the public offering price, less underwriting discounts and commissions. Gross proceeds from the offering will be approximately $1.34 billion.
Moderna is a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients.
For additional details on the offering, please read the press release.